CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 437 enrolled
Drug / intervention
Atrial fibrillation ablationprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00964392
NCT00964392Phase 4Completed
CompareCT.gov

NAVISTAR® THERMOCOOL® Catheter for the Radiofrequency Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation - Post Approval Registry

Biosense Webster, Inc.·interventional·Posted Aug 24, 2009·Updated Feb 4, 2025

In Brief

A Phase 4 clinical trial evaluating Atrial fibrillation ablation for Paroxysmal Atrial Fibrillation. Completed, enrolled 437 participants.

Detailed Summary

The purpose of this registry is to provide additional corroborative short-term safety and long-term safety data for the NAVISTAR THERMOCOOL and NAVISTAR EZ STEER THERMOCOOL catheters in the treatment of symptomatic Paroxysmal Atrial Fibrillation (PAF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParoxysmal Atrial Fibrillation
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 24, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2013
Study CompletionJan 5, 2018
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.9 years ago

Interventions

Atrial fibrillation ablationprocedure

Radiofrequency ablation